F Rest
1 known investors
FREST develops RNA editing therapeutics that leverage endogenous ADAR to target disease-related mRNA without permanent genomic alterations. The company works with pharmaceutical firms and academic partners to advance RNA-level genetic control treatments for diseases with well-defined genetic backgrounds.
BiotechMedical Devices